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Abstract
Background: The understanding the Impact of ulcerative COlitis aNd Its assoCiated disease burden 
on patients study [ICONIC] was a 2-year, global, prospective, observational study evaluating the 
cumulative burden of ulcerative colitis [UC] using the Pictorial Representation of Illness and Self-
Measure [PRISM] tool that is validated to measure suffering, but has not previously been used 
in UC.
Methods: ICONIC enrolled unselected outpatient clinic attenders with recent-onset UC. Patient- 
and physician-reported outcomes including PRISM, the Short Inflammatory Bowel Disease 
Questionnaire [SIBDQ], the Patient Health Questionnaire [PHQ-9], and the Simple Clinical Colitis 
Activity Indexes [patient: P-SCCAI; physician: SCCAI] were collected at baseline and follow-up 
visits every 6  months. Correlations between these measures were assessed using Spearman’s 
rank correlation coefficient.
Results: Overall, 1804 evaluable patients had ≥1 follow-up visit. Over 24  months, mean [SD] 
disease severity measured by P-SCCAI/SCCAI reduced significantly from 4.2 [3.6]/3.0 [3.0] to 2.4 
© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License
(http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any
medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
applyparastyle "fig//caption/p[1]" parastyle "FigCapt"
D
ow
nloaded from
 https://academ
ic.oup.com
/ecco-jcc/advance-article/doi/10.1093/ecco-jcc/jjaa159/5877457 by guest on 24 N
ovem
ber 2020
2 S. Ghosh et al.
[2.7]/1.3 [2.1] [p  <0.0001]. Patient-/physician-assessed suffering, quantified by PRISM, reduced 
significantly over 24 months [p <0.0001]. P-SCCAI/SCCAI and patient-/physician-assessed PRISM 
showed strong pairwise correlations [rho  ≥0.60, p  <0.0001], although physicians consistently 
underestimated these disease severity and suffering measures compared with patients. Patient-
assessed PRISM moderately correlated with other outcome measures, including SIBDQ, PHQ-9, 
P-SCCAI, and SCCAI (rho = ≤-0.38 [negative correlations] or ≥0.50 [positive correlations], p <0.0001).
Conclusions: Over 2  years, disease burden and suffering, quantified by PRISM, improved in 
patients with relatively early UC. Physicians underestimated burden and suffering compared 
with patients. PRISM correlated with other measures of illness perception in patients with UC, 
supporting its use as an endpoint reflecting patient suffering.
Key Words:  PRISM; disease burden; quality of life
1.  Introduction
Ulcerative colitis [UC] is a chronic, idiopathic, progressive inflam-
matory bowel disorder characterised by frequent flares followed by 
periods of remission.1 The burden of UC extends far beyond the clin-
ical signs and symptoms, with certain aspects of the patient’s disease 
affecting many other aspects of life, for example their employment 
opportunities, work productivity, and social interaction.2–5 There is 
an extensive body of literature describing the impact of UC on pa-
tient quality of life and the development of anxiety/depression.2–5 
Anxiety may be caused by multiple factors, including lack of control 
over bodily functions, fear of disease progression and treatment, and 
lack of toilet access.5 In turn, these symptoms may limit employ-
ment opportunities and social and  recreational activities, and such 
issues may contribute to depression.5 Despite the widely documented 
patient-reported burden of UC, physicians often underestimate the 
disease burden and associated suffering, and may fail to recognise 
issues that are important to patients.6
The understanding the Impact of ulcerative COlitis aNd Its 
assoCiated disease burden on patients study [ICONIC] was a 
global, prospective, 24-month, observational study that was ini-
tiated to evaluate the cumulative burden of UC. ICONIC is one 
of the largest studies to date assessing the multifaceted and cumu-
lative burden of UC, and was designed to overcome limitations 
in previous studies. These include inadequate patient populations, 
restricted geographical reach, small number and breadth of the as-
sessment tools applied, absence of both patient and physician per-
spectives, dates of study not reflecting current disease management 
and treatment practices, and limited duration of patient follow-up 
[if any].
The primary objective of ICONIC was to evaluate PRISM 
[Pictorial Representation of Illness and Self-Measure] as an as-
sessment tool for perceived disease-associated suffering in patients 
with UC by assessing its correlation with the Short Inflammatory 
Bowel Disease [IBD] Questionnaire [SIBDQ] and the Patient Health 
Questionnaire [PHQ-9]. Our hypothesis was that such measures 
encompassing disease activity, functional status, illness percep-
tions, and depression will each contribute significantly to suffering 
as measured by PRISM. PRISM has been validated as a reliable 
method for assessing suffering in several chronic conditions, but 
has not previously been used in patients with UC.7–12 In addition, 
ICONIC investigated the multifaceted burden of disease in recently 
diagnosed patients with UC and compared the patient and physician 
perceptions of UC disease through the use of PRISM and the Simple 
Clinical Colitis Activity Index [SCCAI] tools.
2.  Methods
2.1.  Study design and patients
ICONIC was a global, observational, prospective, 24-month, non-
interventional study in patients with UC, with documented follow-up 
visits every 6 months [±3 months] in an outpatient setting, according 
to routine clinical practice. Patients were enrolled at 244 sites from 33 
countries and were grouped according to the United Nations classifica-
tion of economic regions: Western Europe [Austria, France, Germany], 
Eastern Europe [Bulgaria, Czech Republic, Romania, Russia, Slovakia, 
Ukraine], Northern Europe [Estonia, Ireland, Sweden, UK], Southern 
Europe [Bosnia and Herzegovina, Croatia, Greece, Italy, Portugal, 
Serbia, Slovenia, Spain], Canada [Canada], Western Asia [Israel, 
Kuwait, Turkey, Saudi Arabia], Africa [Egypt, South Africa], Latin 
America [Argentina, Chile, Colombia, Mexico], and Japan [Japan]. 
Data collection started June 19, 2015 and ended May 22, 2019.
The inclusion criteria for participants were: aged ≥18 years, diag-
nosed with UC within the previous 36  months, speaking the lan-
guage of the applicable patient questionnaire [23 languages], and 
having signed an authorisation form [and informed consent, where 
applicable] to use and disclose personal health information. As this 
was a non-interventional study, all eligible patients with UC at-
tending their routine clinical visits were offered the opportunity to 
participate, regardless of treatment assignment or disease activity. 
Diagnosis of UC was confirmed by the treating physician; standard-
ised diagnostic criteria were not defined in this observational study.
This observational, prospective study was run in compliance 
with local laws and regulations. Notification/submission to the re-
sponsible ethics committee, health institutions, and/or competent 
authorities was performed as required by local laws and regulations. 
Written patient authorisation to use and/or disclose anonymised 
health data [and informed consent where applicable] was obtained 
before patient inclusion.
2.2.  Assessments
Demographic and disease-related data, medication, information 
on social/educational background, and work productivity/activity 
impairment were recorded. Investigator assessment of UC disease 
severity was measured by clinicians’ global ratings. Patients also self-
assessed their disease severity.
At baseline and each follow-up clinic visit, physicians completed 
the PRISM, SCCAI, and Work Productivity and Activity Impairment 
General Health [WPAI-GH] questionnaires, and patients completed 
the PRISM, SIBDQ, patient-modified SCCAI [P-SCCAI], PHQ-9, 
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and Rating Form of IBD Patient Concerns [RFIPC] questionnaires 
[Supplementary Figure 1, available as Supplementary data at 
ECCO-JCC online]. Translations for the questionnaires and PRISM 
were either obtained directly from the owner of patient-reported 
outcomes, the instrument website, or validated by forwards and 
backwards translation by a third-party vendor (ForeignExhange 
Translations, located in Newton, MA, USA). Physicians and pa-
tients completed PRISM separately at the same visit to avoid bias. 
Associated comorbidities and symptoms, extra-intestinal manifest-
ations [EIMs], other concomitant immune-mediated diseases, and 
medications at each visit were evaluated by closed-form questions 
with predefined categories. Possible answers for EIMs and other 
concomitant immune-mediated diseases included ankylosing spon-
dylitis [AS], erythema nodosum [EN], hidradenitis suppurativa, 
primary sclerosing cholangitis, psoriasis, psoriatic arthritis, pyo-
derma gangrenosum, rheumatoid arthritis [RA], uveitis, other, or 
none.13 Non-specific arthralgia and arthritis were not included due 
to difficulty in ensuring consistent reporting across the geographical 
regions. Health care resource use questionnaires captured param-
eters including hospitalisation rates and surgery over the preceding 
6 months due to UC.
2.3.  Patient- and physician-reported outcome 
measures
The PRISM measure is based on a visual metaphor [Supplementary 
Figure 2, available as Supplementary data at ECCO-JCC online]. 
Patients are presented with a rectangular paper sheet with a yellow 
disc in the bottom right corner, instructed to imagine that the sheet 
represents ‘your life at the moment’ and the yellow disc represents 
‘yourself’. They are also given a red disc, which they are told repre-
sents ‘your UC’, and are asked, ‘please place the red disc on the sheet 
to show the importance of your UC in ‘your life at the moment’’. The 
closer the red ‘illness’ disc is to the yellow ‘self’ disc, the greater the 
person’s suffering.14,15 The distance between the centres of the yellow 
and red discs is termed the Self-Illness Separation [SIS]. The smaller 
the value of SIS, the greater the person’s suffering. In this study, the 
range of SIS was 0–9.4 cm.
SIBDQ includes 10 items scored from 1 [severe problem] to 7 
[no problem at all] that capture the impact of IBD on four domains: 
bowel symptoms, systemic symptoms, emotional function, and so-
cial function. The total SIBDQ score is calculated as the sum of the 
10 items [range: 10–70]. Higher SIBDQ scores reflect better health-
related quality of life [HRQoL].16
SCCAI evaluates disease severity during the previous week by 
measuring bowel frequency [day], urgency of defaecation, blood in 
stool, bowel frequency [night], general well-being, and extra-colonic 
features, and the total SCCAI is calculated as the sum of these 
six measures [range: 0–19], with a higher score indicating greater 
symptom severity.17 P-SCCAI comprises 12 items, scored by the pa-
tient using different scales for the same measures.18
RFIPC is an IBD-specific questionnaire comprising questions re-
lated to the 25 most frequently reported worries/concerns reported 
by patients with IBD. Responses are scored on 10-cm visual analogue 
scales [0 cm: no worries/concerns; 10 cm: the greatest possible wor-
ries and concerns] and a mean score of all items is calculated [range: 
0–10], with higher scores indicating greater worry and concern.19
PHQ-9 is a nine-item instrument for screening, diagnosing, moni-
toring, and measuring the severity of depression. Each item is scored 
from 0 [not at all] to 3 [nearly every day] and the PHQ-9 score is the 
sum of the nine items [range: 0–27].20
WPAI-GH is a six-item instrument, a self-report survey of impair-
ments in work-related outcomes due to general health problems over 
the previous 7 days. Patients’ responses to items are used to calcu-
late the impact of their general health on four domains: absenteeism 
[work time missed], presenteeism [impairment while working], 
overall work impairment [overall productivity loss, accounting for 
both absenteeism and presenteeism], and total activity impairment 
[impairment in non-work activities]. Scores from all domains are ex-
pressed as percentages of impairment, with lower values indicating 
less impairment.21 WPAI-GH only includes employed patients.
2.4.  Statistical analysis
The evaluable population comprised all patients who fulfilled the 
study selection criteria and had ≥1 post-baseline visit. Quantitative 
data were presented as mean (standard deviation [SD] and me-
dian [range]). Qualitative data [eg, gender] were presented using 
means of frequency distributions. Calculation of percentages was 
based on the valid data per parameter, ie, excluding patients with 
missing values. Analysis by geographical region was descriptive only. 
P-SCCAI scores were transformed to be equivalent to the SCCAI 
scoring. Spearman’s rank correlation coefficient [rho] was used to 
assess correlations at baseline and at each follow-up visit between 
the outcomes of patient-assessed PRISM and physician-assessed 
PRISM, SIBDQ, SCCAI, P-SCCAI, RFIPC, and PHQ-9, as well as 
the correlation between patient and physician PRISM and SCCAI 
scores. Statistical significance was determined using exact critical 
probability [p] values. For this analysis, SAS® package version 9.4 
was used and all scores were treated as quantitative variables.
3.  Results
3.1.  Study sites and patient baseline characteristics
Overall, 1804 evaluable patients fulfilled the selection criteria and 
had ≥1 follow-up visit. The total number of evaluable patients at 
each visit [excluding patients with missing values] are shown in 
Supplementary Table 1, available as Supplementary data at ECCO-
JCC online. In total, 244 sites participated, with Southern Europe re-
cruiting the largest number of patients [n = 415] [Table 1]. University 
hospitals made up just under half of the study sites [44.7%], and 
>90% of sites were located in an urban setting. Most sites [86.4%] 
saw an average of ≤1000 patients with UC per year, and approxi-
mately 45.0% of sites saw each patient with UC ≥4 times per year.
Of the 1804 patients with data at baseline, 53.8% [n = 970] were 
female and 50.1% [n = 903] of all patients had mild UC or were 
in remission, as assessed by the physician. Most patients (71.4% 
[n = 1287/1803]) had experienced symptoms for <1 year before diag-
nosis. Aminosalicylates were the most commonly prescribed drugs at 
baseline, followed by steroids and immunotherapy [Table 1]. Two-
thirds (63.1% [n  =  1139/1804]) of patients were employed. Sick 
leave was attributable to UC [patient-reported] for approximately 
two-thirds of patients who were on sick leave [n = 191/292], and al-
most one-quarter of the unemployed patients [n = 45/189] attributed 
their unemployment to UC [Table 1]. Patient baseline characteristics 
for the geographical regions are shown in Supplementary Table 2, 
available as Supplementary data at ECCO-JCC online.
3.2.  Change in patient disease characteristics from 
baseline to month 24
3.2.1.  Hospitalisation and surgery
At baseline, 27.5% [n = 495/1799] of patients reported being ad-
mitted to hospital due to UC within the preceding 6 months. Over 
time, the proportion of patients hospitalised for UC in the 6 months 
preceding each study visit decreased to 4.0% [n = 52/1298] at the 
D
ow
nloaded from
 https://academ
ic.oup.com
/ecco-jcc/advance-article/doi/10.1093/ecco-jcc/jjaa159/5877457 by guest on 24 N
ovem
ber 2020
4 S. Ghosh et al.
24-month visit. Similarly, there was a concordant reduction in 
the number of patients with new surgeries due to UC: from 2.5% 
[n = 44/1794] at baseline to 1.3% [n = 17/1294] at 24 months.
3.2.2. Associated immune-mediated extra-intestinal 
manifestations
At baseline, 14.4% of patients [n = 253/1763] experienced ≥1 asso-
ciated immune-mediated EIM [Table 1]; the most common were EN 
[1.3%], AS [1.3%], and RA [1.2%]. These EIMs continued to be the 
most frequently diagnosed during the 24-month study: 2.2% of pa-
tients were diagnosed with RA at least once, 2.0% of patients with 
EN at least once, and 1.8% of the patients with AS at least once until 
Month 24. The proportion of patients who were diagnosed with any 
associated immune-mediated EIM increased over time to 24.0% 
[n = 332/1382; Month 24].
When analysed by geographical region, numerically fewer pa-
tients in Japan were diagnosed with associated immune-mediated 
EIMs compared with patients in the other regions (baseline: 3.6% 
Table 1. Patient baseline and disease characteristics.
Characteristic Patients n = 1804a
Female, n [%] 970 (53.8)
Age, median [range], years 36.0 (18.0–88.0)
Geographic region,b n [%]  
 Western Europe 145 (8.0)
 Eastern Europe 327 (18.1)
 Northern Europe 150 (8.3)
 Southern Europe 415 (23.0)
 Canada 129 (7.2)
 Western Asia 217 (12.0)
 Africa 100 (5.5)
 Latin America 204 (11.3)
 Japan 117 (6.5)
UC physician-assessed disease severity, n [%]  
 Mild 673 (37.3)
 Moderate 667 (37.0)
 Severe 233 (12.9)
 In remission 230 (12.8)
 Missing 1 (0.1)
UC patient-assessed disease severity, n [%]  
 Mild 614 (34.1)
 Moderate 665 (36.9)
 Severe 235 (13.0)
 In remission 286 (15.9)
 Missing 4 (0.2)
Duration of symptoms prior to  
diagnosis, n [%]
 
 <1 year 1287 (71.4)
 1–3 years 383 (21.2)
 >3 years 133 (7.4)
 Missing 1 (0.1)
Time since diagnosis, median [range], daysc 172.0 (-14.0–1095.0)
UC treatment at baseline, n [%]d  
 5-ASA/mesalamine 998 (55.3)
 Sulphasalazine 32 (1.8)
 Aminosalicylates 316 (17.5)
 Immunotherapy [azathioprine,
  6-mercatopurine, methotrexate, cyclo-
sporin, tacrolimus]
284 (15.7)
 Steroids [IV, oral] 312 (17.3)
 Biologics [TNFi and non-TNFi] 190 (10.5)
Employment status, n [%]  
 Employed/self-employed 1139 (63.1)
 On sick leave 292 (16.2)
   Sick leave related to UC [in patients on 
sick leave]
191 (65.4)
 Unemployed 189 (10.5)
   Unemployment related to UC [in  
unemployed patients]
45 (23.8)
Duration of sick leave, n [% of total patients 
on sick leave]
n = 292
 <2 months 141 (48.3)
 ≥2 to ≤4 months 27 (9.3)
 >4 months 48 (16.4)
 Missing 76 (26.0)
Duration of unemployment, n [% of total 
unemployed patients]
n = 189
 <6 months 45 (23.8)
 ≥6 months to ≤12 months 28 (14.8)
 >12 months 78 (41.3)
 Missing 38 (20.1)
Associated immune-mediated  
extra-intestinal manifestations,e n [%]
 
 0 1510 (83.7)
Characteristic Patients n = 1804a
 1 227 (12.6)
 2 20 (1.1)
 3 6 (0.3)
 Missing 41 (2.3)
Associated comorbid diseases and 
symptoms,f n [%]
 
 0 968 (53.7)
 1–3 508 (28.2)
 4–6 34 (1.9)
 7–10 2 (0.1)
 >10 268 (14.9)
 Missing 24 (1.3)
ASA, aminosalicylic acid; IV, intravenous; n, number of patients; TNFi, 
tumour necrosis factor inhibitor; UC, ulcerative colitis.
a21 patients were excluded from the evaluable population due to violation 
of the selection criteria.
bPatients were enrolled at 244 sites from 33 countries in nine regions: 
Western Europe [Austria, France, Germany], Eastern Europe [Bulgaria, Czech 
Republic, Romania, Russia, Slovakia, Ukraine], Northern Europe [Estonia, 
Ireland, Sweden, UK], Southern Europe [Bosnia and Herzegovina, Croatia, 
Greece, Italy, Portugal, Serbia, Slovenia, Spain], Canada [Canada], Western 
Asia [Israel, Kuwait, Turkey, Saudi Arabia], Africa [Egypt, South Africa], 
Latin America [Argentina, Chile, Colombia, Mexico], Japan [Japan].
cTime since UC diagnosis (calculated as difference between date of UC 
diagnosis and visit date, days). The 15th day was used as the default diag-
nosis date; therefore, negative values can occur. All patients included in the 
study had a confirmed UC diagnosis before Visit 1 (baseline visit).
dn-values combined within each class of medication.
eCaptured by the physician; possible answers on the case report form 
included previously diagnosed with: ankylosing spondylitis, erythema 
nodosum, hidradenitis suppurativa, primary sclerosing cholangitis, psoriasis, 
psoriatic arthritis, pyoderma gangrenosum, rheumatoid arthritis, uveitis, 
other, or ‘the patient has not been reported to have any extra-intestinal mani-
festation’.
fCaptured by the physician; possible answers on the case report form 
included anxiety/depression, any malignancies, cardiac abnormalities/cardio-
vascular disease, chronic renal disease or insufficiency, chronic pulmonary 
disease, cognitive dysfunction, diabetes mellitus, fatigue, low body weight 
<20 body mass index, polyneuropathy/neuropathy, postural hypotension, 
skin disease, and sleep disorders.
Table 1. Continued
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[n = 4/111] vs 11.4% [n = 23/201] to 19.7% [n = 29/147]; Month 
24: 7.1% [7/99] vs 20.8% [33/159] to 35.0% [35/100]).
3.2.3.  Associated comorbid diseases and symptoms
Overall, 45.6% [n = 812/1780] of patients were diagnosed with any 
associated comorbid diseases and symptoms at baseline, with a ma-
jority having one to three comorbidities [Table 1]; the most common 
were fatigue [27.7% of patients], anxiety/depression [24.8%], sleep 
disorders [20.6%], and cardiac abnormalities/cardiovascular dis-
ease [20.5%]. During the study, the proportion of patients diag-
nosed with any new associated comorbid diseases and symptoms at 
baseline at each follow-up visit remained relatively constant [range: 
6.6–8.8%]. At Month 24, the most commonly diagnosed new asso-
ciated comorbid diseases and symptoms since baseline were anxiety/
depression (1.8% [n = 32/1804]) and fatigue (1.7% [n = 30/1804]).
The proportion of patients diagnosed with any associated 
comorbid diseases and symptoms at baseline was lowest in Japan 
compared with the other regions (19.8% [n  =  23/116] vs 40.3% 
[n = 167/414] to 67.0% [n = 67/100]). Furthermore, the proportion 
of patients diagnosed with any new associated comorbid diseases 
and symptoms at each follow-up visit remained lower in Japan rela-
tive to the other regions [0.0–1.0% vs 2.6–17.5%].
3.2.4.  Pictorial representation of illness and self-measure
Compared with physician-completed PRISM scores, patients showed 
lower PRISM scores throughout the study, indicating that patients 
reported greater suffering than physicians did, and that physicians 
may have underestimated the severity of disease in their patients 
[Figure 1]. Between baseline and Month 24, the mean [SD] SIS sig-
nificantly increased from 4.0 [2.5] to 5.1 [2.5] for patient-completed 
PRISM (mean [SD] difference of 1.2 [3.0]; p  <0.0001), and from 
4.3 [2.4] to 5.6 [2.4] for physician-completed PRISM (mean [SD] 
difference of 1.3 [2.9]; p <0.0001), with increases in SIS indicating 
a reduction in suffering. There was a significant difference between 
patient and physician mean scores at baseline (mean [SD] change dif-
ference of 0.3 [2.2]; p <0.0001) and at Month 24 (mean [SD] change 
difference of 0.5 [2.1]; p <0.0001). Physician- and patient-assessed 
PRISM scores were strongly correlated at each visit {PRISM patient 
vs physician: rho = 0.60 (95% confidence interval [CI]: 0.56–0.62) 
to 0.67 (95% CI: 0.64–0.70); p <0.0001} [Table 2].
Mean patient- and physician-completed PRISM scores varied 
by region [Supplementary Table 3] , available as Supplementary 
data at ECCO-JCC online, with lower physician-completed 
PRISM scores reported throughout the 24-month follow-up 
period among patients in Japan compared with other regions. 
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Figure 1. PRISM and other patient- and physician-reported outcomes in the overall ICONIC population. [A] Physician- [left panel] and patient-assessed [right 
panel] PRISM SIS over 24  months. The 5-number summary shown in the box and whisker plot is the minimum, first quartile, median, third quartile, and 
maximum. [B] Mean [SD] SIBDQ score over 24 months. [C] Mean [SD] RFIPC score over 24 months. [D] Mean [SD] PHQ-9 score over 24 months. [E] Mean 
[SD] SCCAI and P-SCCAI score over 24  months. ***p  <0.0001 vs baseline. Statistical analysis was calculated using the Wilcoxon signed-rank test. PHQ-9, 
Patient Health Questionnaire; P-SCCAI, patient-modified SCCAI; PRISM, Pictorial Representation of Illness and Self-Measure; RFIPC, Rating Form of IBD Patient 
Concerns; SCCAI, Simple Clinical Colitis Activity Index; SIBDQ, Short Inflammatory Bowel Disease Questionnaire; SIS, Self-Illness Separation; IBD, inflammatory 
bowel disease; ICONIC, Impact of ulcerative COlitis aNd Its assoCiated disease burden on patients.
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At Months 12–24, patient-completed PRISM scores were higher 
[indicating less suffering] than physician-completed scores in 
Japan. Patients in Africa showed the greatest change difference 
in patient- and physician-completed PRISM score by Month 24 
[Supplementary Table 3].
3.3  Change in patient/physician assessment of 
disease from baseline to Month 24
3.3.1.  Disease severity as measured by physicians or patients
Approximately half of all patients were categorised by phys-
icians or self-assessed their disease severity as moderate or severe 
[Table 1].
The proportion of patients assessed by physicians as being 
in remission increased from baseline to Month 24 (12.8% 
[n = 230/1803] vs 53.4% [n = 694/1299]), whereas the proportion 
of patients with mild disease remained similar over time (baseline: 
37.3% [n = 673/1803]; Month 24: 30.9% [n = 401/1299]). Similar 
results were observed for patient-assessed disease severity over the 
24-month study period; at each visit a higher proportion of patients 
self-assessed their disease as severe than physicians did.
Change in physician and patient assessment of disease severity 
over time was similar across all regions. However, the highest 
and lowest proportion of patients with severe disease at baseline 
were reported in Africa (physician- and patient-assessed: 22.0% 
[n  =  22/100]) and Japan (physician- and patient-assessed: 3.4% 
[n = 4/116–117]), respectively, relative to other regions (physician-
assessed: 9.2% [n = 38/414] to 17.5% [n = 38/217]; patient-assessed: 
9.6% [n = 40/415] to 17.2% [n = 25/145]).
3.3.2.  Disease activity as measured by the SCCAI and P-SCCAI
At baseline and Month 24, the mean [SD] total SCCAI was sig-
nificantly lower than P-SCCAI (baseline: 3.0 [3.0] vs 4.2 [3.6]; 
p <0.0001; Month 24: 1.3 [2.1] vs 2.4 [2.7]; p <0.0001) [Figure 1]; 
however, there was a strong correlation between SCCAI and 
P-SCCAI throughout the study (SCCAI vs P-SCCAI: rho  =  0.65 
[95% CI: 0.62–0.68] to 0.73 [95% CI: 0.71–0.75]; p  <  0.0001) 
[Table 2]. Between baseline and Month 24, the mean [SD] P-SCCAI 
significantly decreased from 4.2 [3.6] to 2.4 [2.7] (mean [SD] differ-
ence of -1.6 [4.0]; p <0.0001] and SCCAI from 3.0 [3.0] to 1.3 [2.1] 
(mean [SD] difference of -1.6 [3.2]; p <0.0001) [Figure 1].
Patients from Western Asia and Africa reported the highest 
P-SCCAI (mean [SD]: 5.2 [3.9–4.0]) at baseline relative to other 
regions [mean: 3.4–4.7], whereas patients in Southern Europe 
generally reported the lowest P-SCCAI throughout the study 
[Supplementary Table 4, available as Supplementary data at ECCO-
JCC online]. At baseline and Month 24, mean SCCAI was the lowest 
in Japan, followed closely by Latin America and Southern Europe 
[Supplementary Table 4].
3.3.3.  Other patient-reported outcomes
Mean [SD] SIBDQ scores significantly increased (48.3 [13.2] base-
line vs 56.0 [11.5] Month 24; mean [SD] difference of 7.1 [14.0]; 
p <0.0001) during the study (suggesting an improvement in HRQoL) 
[Figure  1]. Mean [SD] PHQ-9 scores significantly decreased (6.3 
[5.4] baseline vs 4.1 [4.5] Month 24; mean [SD] difference of -1.9 
[5.4]; p  <0.0001) and mean (SD) RFIPC scores significantly de-
creased (3.4 [2.2] baseline vs 2.7 [2.3] Month 24; mean [SD] differ-
ence of -0.7 [2.4]; p <0.001) during the study, suggesting a reduction 
in UC-associated symptom severity, depression, and worry and con-
cern, respectively [Figure 1]. The measures were generally consistent 
across regions, except for mean RFIPC score, which was generally 
higher [indicating greater worry and concern] among patients in 
Latin America and Japan. Patients in Africa showed the greatest 
mean difference across the measures by Month 24 [Supplementary 
Table 4].
At baseline, among the 1140 employed patients, mean present-
eeism [percentage of impairment experienced at work] was 27.7%, 
mean absenteeism was 16.0%, and mean total work productivity im-
pairment was 32.2% [Figure 2]. The mean total activity impairment 
irrespective of the patients’ employment status was 34.4% [Figure 2]. 
During the study, patients showed a gradual [11.1–14.6%] decrease 
[suggesting an improvement] in absenteeism (mean [SD] difference 
of -11.1% [32.6]), presenteeism (mean [SD] difference of -12.0% 
[32.4]), total work productivity impairment (mean [SD] difference of 
-14.6% [36.2]), and total activity impairment (mean [SD] difference 
of -14.4% [33.6]) by Month 24 [Figure 2].
There were decreases in all WPAI-GH parameters [suggesting an 
improvement] over time across all regions, except for presenteeism 
in Japan, which showed minimal decrease [Supplementary Table 5, 
available as Supplementary data at ECCO-JCC online].
3.4.  Correlations of PRISM [patient] with other 
patient- and physician-reported outcomes
At baseline and all follow-up visits to Month 24, there was a mod-
erate positive correlation between patient-assessed PRISM scores 
and SIBDQ (rho  =  0.50 [95% CI: 0.47–0.54] to 0.55 [95% CI: 
0.51–0.59]; p  <0.0001), and a moderate negative correlation be-
tween patient-assessed PRISM scores and PHQ-9 (rho = -0.41 [95% 
CI: -0.45 to -0.37] to -0.43 [95% CI: -0.47 to -0.38]; p <0.0001). 
Similarly, moderate negative correlation findings were also reported 
between PRISM [patient] and SCCAI (rho = -0.38 [95% CI: -0.42 
to -0.34] to -0.44 [95% CI: -0.48 to -0.39]; p <0.0001), P-SCCAI 
(rho = -0.43 [95% CI: -0.47 to -0.40] to -0.50 [95% CI: -0.54 to 
-0.45]; p <0.0001), and RFIPC (rho = -0.40 [95% CI: -0.44 to -0.36] 
to -0.46 [95% CI: -0.50 to -0.42]; p <0.0001) [Table 3].
Table 2. Correlation between patient and physician perceptions of 
ulcerative colitis.
Visit Number of  
patients
Spearman correlation 
coefficient [95% CI]
p-value
PRISM [patient] vs PRISM [physician]
 Visit 1 (baseline) 1790 0.60 [0.56–0.62] <0.0001
 Visit 2 (Month 6) 1558 0.61 [0.58–0.64] <0.0001
 Visit 3 (Month 12) 1414 0.65 [0.62–0.68] <0.0001
 Visit 4 (Month 18) 1298 0.67 [0.64–0.70] <0.0001
 Visit 5 (Month 24) 1243 0.63 [0.60–0.66] <0.0001
SCCAI vs P-SCCAI    
 Visit 1 (baseline) 1791 0.73 [0.71–0.75] <0.0001
 Visit 2 (Month 6) 1559 0.72 [0.69–0.74] <0.0001
 Visit 3 (Month 12) 1428 0.71 [0.69–0.74] <0.0001
 Visit 4 (Month 18) 1322 0.65 [0.62–0.68] <0.0001
 Visit 5 (Month 24) 1272 0.67 [0.64–0.70] <0.0001
Statistical significance was calculated using exact critical probability [p] 
values.
CI, confidence interval; PRISM, Pictorial Representation of Illness and 
Self-Measure; P-SCCAI, patient-modified SCCAI; SCCAI, Simple Clinical 
Colitis Activity Index.
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4.  Discussion
This global study, ICONIC, includes data from approximately 1800 
patients with recently diagnosed UC [244 sites, 33 countries], re-
gardless of their treatment and is among the largest studies to date 
in assessing the multifaceted and cumulative burden of UC. The pro-
spective 24-month, non-interventional study provides useful insights 
into how UC and its associated disease burden, including patient 
suffering, evolve over time and how PRISM can be used as an assess-
ment tool for suffering in patients with UC.
The primary objective of ICONIC was to evaluate PRISM as an 
assessment tool for perceived disease-associated suffering in UC. The 
results presented here demonstrate that suffering, as measured by 
patient-assessed PRISM, correlated significantly with other patient- 
and physician-reported outcomes of UC disease activity, depres-
sion, HRQoL, and worry/concern. Furthermore, either patient- or 
physician-assessed PRISM SIS scores reduced significantly over the 
2-year study period, a trend that was also observed with disease 
activity scores in ICONIC. These observed correlations provide 
further confirmation that PRISM is an appropriate tool for the as-
sessment of patient burden. However, as correlations with other as-
sessment tools were only moderate, each tool clearly reflects distinct 
disease aspects, and their conjoint use remains justified.
PRISM is a tool that uses a visual metaphor to measure the 
burden of suffering,14,15 which fits with the widely used concep-
tualisation of suffering established by Cassel in the early 1980s.22 
Disease activity, functional status, illness perceptions, and depres-
sion can all contribute to suffering,22 and therefore measurement of 
suffering is a good candidate for a single, patient-centred outcome 
measure. Furthermore, alternative questionnaire-based tests can be 
time consuming and burdensome for physicians and patients, and 
their use is generally limited to trial settings. By contrast, PRISM can 
be easily completed by patients in <5 min during routine medical 
consultations, with immediate results.15 In addition, being an essen-
tially visual tool with simple instructions, PRISM yields comparable 
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results across languages and cultures.15 If used regularly throughout 
the course of managing patients with UC, PRISM has the potential 
to unmask increasing disease burden associated with the progression 
of UC, even in patients who may be deemed to be in remission. Thus, 
PRISM may have a role in goal-oriented treatment approaches, 
which aim to measure the extent to which people are able to achieve 
their personal goals for treatment with minimum burden of disease, 
and to inform discussion and reappraisal of goals, as well as adjust-
ment of treatment, when goals are not met.
To our knowledge, PRISM has not previously been used in 
patients with UC, although the correlation of the burden of suf-
fering measured by PRISM with conventionally used patient- and 
physician-reported outcomes is consistent with findings in other dis-
eases [eg, RA, systemic lupus erythematosus, pain, advanced cancer, 
tinnitus, and liver disease].7–12,15 In these studies, PRISM SIS showed 
good correlations with other illness measures, with correlation 
strength varying according to diagnosis and also between samples 
with the same diagnosis.15
One secondary objective of ICONIC was to compare patient 
and physician perceptions of disease. Physician- and patient-assessed 
PRISM SIS scores were strongly correlated at each visit, indicating 
a similar gradual reduction in suffering over time. However, at each 
visit the mean SIS score was significantly higher for the physician 
vs patient assessment, highlighting an underestimation of patient 
suffering by physicians. Similar findings were also reported for the 
physician-assessed SCCAI and patient-assessed P-SCCAI, with phys-
icians reporting lower disease activity. Furthermore, despite phys-
icians assessing that over half of all patients had mild UC or were 
in remission at baseline, nearly two-thirds of patients who reported 
sick leave said their sick leave was attributable to UC. Collectively, 
these data suggest there remains a disconnect between physicians 
and patients in understanding the burden of patients’ disease. These 
differences warrant further investigation in the future.
One factor potentially contributing to differences between pa-
tients and physicians in appraising UC-related burden is the quality 
of physician-patient communication, but other factors may also 
be influential.23 These findings are consistent with previous re-
sults, demonstrating differences between patients’ self-perceived 
experiences with UC and their health care providers’ [including 
physicians’] estimates of UC disease burden.6,24 Efforts to increase 
physicians’ understanding of the suffering experienced by patients 
with UC are key to promoting more appropriate decision making re-
garding treatment. As an adjunct to standard measures of disease as-
sessment, PRISM can serve as a tool for improving patient-physician 
communication.15,25 For example, after the patient has completed the 
PRISM task, simply asking why they put the illness disc where they 
did usually elicits a highly pertinent but very succinct answer.
Another secondary objective of ICONIC was to describe the 
multifaceted burden of disease in recently diagnosed patients 
with UC. Overall, the study showed that burden and suffering 
for patients with early UC reduced over time through 2 years of 
follow-up. First, this was demonstrated by a series of physician- 
and/or patient-completed questionnaire-based tests, including the 
SCCAI, SIBDQ, RFIPC, PHQ-9, and WPAI-GH, which are recog-
nised to collectively assess disease activity, aspects of physical and 
mental health, work productivity, and activity impairment in pa-
tients with UC.26,27
Furthermore, both physician and patient assessments indicated 
an increase in UC remission and a reduction in disease severity over 
the 2-year study period. The improvement in disease severity may 
have resulted from patients receiving more stringent management, 
or improved patient compliance during the study. As ICONIC was 
a non-interventional study, the influence of treatment regimen on 
disease activity is out of scope for this study. The proportion of pa-
tients with ≥1 associated immune-mediated EIM was relatively low 
at baseline, increasing slightly over time, with RA, EN, and AS re-
maining the three most common associated immune-mediated EIMs 
throughout. Associated comorbid diseases and symptoms were also 
common among patients in the study, consistent with findings else-
where,28 affecting almost half of the patients at baseline. Fatigue was 
the most common symptom experienced at baseline, and it increased 
in incidence over time, despite patients experiencing an improvement 
in disease severity; indeed, fatigue has been reported as a prevalent 
and frequently under-recognised, undermanaged symptom in pa-
tients with UC.29–31
Last, this study assessed patient suffering and burden by nine 
geographical regions [Western Europe, Eastern Europe, Northern 
Europe, Southern Europe, Canada, Western Asia, Africa, Latin 
America, Japan]. Although the analyses from each geographical re-
gion followed the same trends as the overall results of the study, 
some regional differences were observed. Throughout the 2-year 
follow-up period, patients in Japan generally had lower patient- and 
Table 3. Correlation of patient-assessed PRISM with other patient- 
and physician-reported outcomes.
Visit Number of 
patients
Spearman correlation 
coefficient [95% CI]
p-value
PRISM [patient] vs SIBDQ
 Visit 1 (baseline) 1782 0.50 [0.47–0.54] <0.0001
 Visit 2 (Month 6) 1558 0.52 [0.48–0.56] <0.0001
 Visit 3 (Month 12) 1413 0.54 [0.50–0.58] <0.0001
 Visit 4 (Month 18) 1299 0.55 [0.51–0.59] <0.0001
 Visit 5 (Month 24) 1247 0.55 [0.51–0.59] <0.0001
PRISM [patient] vs PHQ-9 
 Visit 1 (baseline) 1788 -0.41 [-0.45–-0.37] <0.0001
 Visit 2 (Month 6) 1562 -0.41 [-0.45–-0.37] <0.0001
 Visit 3 (Month 12) 1415 -0.41 [-0.45–-0.36] <0.0001
 Visit 4 (Month 18) 1301 -0.44 [-0.48–-0.40] <0.0001
 Visit 5 (Month 24) 1247 -0.43 [-0.47–-0.38] <0.0001
PRISM [patient] vs RFIPC
 Visit 1 (baseline) 1775 -0.40 [-0.44–-0.36] <0.0001
 Visit 2 (Month 6) 1555 -0.39 [-0.43–-0.35] <0.0001
 Visit 3 (Month 12) 1409 -0.41 [-0.45–-0.37] <0.0001
 Visit 4 (Month 18) 1298 -0.45 [-0.49–-0.41] <0.0001
 Visit 5 (Month 24) 1242 -0.46 [-0.50–-0.42] <0.0001
PRISM [patient] vs P-SCCAI
 Visit 1 (baseline) 1783 -0.43 [-0.47–-0.40] <0.0001
 Visit 2 (Month 6) 1555 -0.49 [-0.52–-0.45] <0.0001
 Visit 3 (Month 12) 1413 -0.49 [-0.53–-0.45] <0.0001
 Visit 4 (Month 18) 1297 -0.49 [-0.53–-0.45] <0.0001
 Visit 5 (Month 24) 1240 -0.50 [-0.54–-0.45] <0.0001
PRISM [patient] vs SCCAI
 Visit 1 (baseline) 1790 -0.38 [-0.42–-0.34] <0.0001
 Visit 2 (Month 6) 1557 -0.43 [-0.47–-0.39] <0.0001
 Visit 3 (Month 12) 1409 -0.41 [-0.45–-0.36] <0.0001
 Visit 4 (Month 18) 1299 -0.43 [-0.47–-0.38] <0.0001
 Visit 5 (Month 24) 1246 -0.44 [-0.48–-0.39] <0.0001
CI, confidence interval; PRISM, Pictorial Representation of Illness and 
Self-Measure; PHQ-9, Patient Health Questionnaire; P-SCCAI, patient-
modified SCCAI; RFIPC, Rating Form of IBD Patient Concerns; SCCAI, 
Simple Clinical Colitis Activity Index; SIBDQ, Short Inflammatory Bowel 
Disease Questionnaire.
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physician-reported PRISM scores [indicating that patients from 
Japan appraised their suffering as greater] compared with other 
geographical regions. Despite this, patients in Japan showed consist-
ently more favourable results with the other patient- and physician-
reported outcomes (Supplementary Table 3). Furthermore, patients 
from Africa were consistently the most ‘unwell’ at baseline and 
showed the greatest mean difference in score across most of the 
patient- and physician-reported outcomes by 24-month follow-up. 
Visual metaphors—including PRISM—are interpreted by people in 
personally meaningful ways, and therefore yield personal assess-
ments. The observed differences between regions may, in part, reflect 
differing perceptions across cultures of what constitutes suffering 
and to what degree one suffers as a product of disease. Cross-cultural 
comparisons may be complicated by different understandings be-
tween cultures of the chosen subject, in this case suffering associated 
with UC. There is also evidence that perceptual processes may differ 
between cultures, with people from Eastern cultures paying more at-
tention to context than those from Western cultures.17
ICONIC has several strengths, including its prospective design, 
large sample size, and the fact that patient outcomes were measured 
using a variety of patient and physician assessment tools. The find-
ings are limited by the fact that it is not a population based study and 
has no predefined region-specific sample size. Furthermore, changes 
in disease burden relative to the patients’ treatment regimens were 
not explored. Despite ICONIC being a non-interventional study, 
some patients may have received more stringent management, or 
patient compliance may have improved over time. By its nature, 
UC is a progressive disease in a significant proportion of patients, 
advancing from limited to more extensive involvement of the colon, 
and it can lead to complications, such as neoplasia. ICONIC had 
a 2-year follow-up duration, which did not afford the opportunity 
to study the possible contributions of PRISM toward assessing pro-
gression of UC over longer periods. Studies over a longer period 
will be necessary to establish whether the suffering of the patients is 
related to disease progression. Finally, self-reported outcomes, such 
as questionnaire results, are inherently prone to self-presentational 
and recall biases.
In conclusion, this first assessment of PRISM in UC showed that 
patient-assessed PRISM scores correlated with other patient- and 
physician-reported outcomes [SCCAI, P-SCCAI, SIBDQ, RFIPC, and 
PHQ], consistent with our hypothesis that disease activity, quality 
of life, and depression will each contribute significantly to suffering 
as measured by PRISM. These findings from ICONIC confirm that 
PRISM SIS scores are a good indicator of perceived illness burden in 
patients with UC and may be used to follow up on changes in disease-
related suffering. These longitudinal data support the use of PRISM 
as an additional outcome measure in future clinical trials in UC, to 
sit alongside standardised UC questionnaires that measure more spe-
cific patient- and physician- reported outcomes. Furthermore, this 
study also adds to the evidence base that, in patients with UC, disease 
burden and suffering continue to be underestimated by physicians. 
PRISM may be used to enhance patient-physician communication 
and identify patients with UC who have a high level of suffering and 
may be at risk of developing psychological disorders, and therefore 
require increased care.25
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